Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
Healthcare
$14.16 +1.49%
+$0.37 today
- Market cap
- $1.25B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
52W Low $12.59High $47.65
Volume 1.17M
Average 1.48M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$142.42M
FY 2025 · Annual
Investing Cash Flow
-$389.75M
FY 2025 · Annual
Financing Cash Flow
$591.00M
FY 2025 · Annual
+408.9% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Depreciation & Amortization | 0 | 0 | 0 | 43K | 59K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 80K | 455K | 5.06M | 11.34M | 19.32M |
| Change in Working Capital | 4.09M | 772K | (7.47M) | 9.52M | 2.73M |
| Accounts Receivables | 0 | 0 | (355K) | 424K | (166K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 4.09M | 772K | (7.12M) | 9.1M | 2.9M |
| Other Non-Cash Items | 684K | (649K) | (6.87M) | (9.41M) | (9.88M) |
| Operating Cash Flow | (14.56M) | (29.22M) | (81.17M) | (166.31M) | (142.42M) |
| Capital Expenditures | 0 | 0 | 0 | (96K) | (15K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (71.76M) | (347.97M) | (373.45M) | (814.74M) |
| Sales of Investments | 0 | 50M | 187.5M | 488.5M | 425M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (21.76M) | (160.47M) | 114.96M | (389.75M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 23.81M | 0 | 202.99M | 116.06M | 591M |
| Common Stock Repurchased | 0 | (1.63M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 258K | 83K | 0 |
| Financing Cash Flow | 23.81M | 128.02M | 203.25M | 116.14M | 591M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 9.25M | 77.04M | (38.4M) | 64.79M | 58.83M |
| Free Cash Flow | (14.56M) | (29.22M) | (81.17M) | (166.41M) | (142.43M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$154.7M
+ D&A$59.0K
+ Stock-Based Comp$19.3M
+ Deferred Tax$0
+ Working Capital$2.7M
- Other Non-Cash-$9.9M
= Operating Cash Flow-$142.4M
- Capex-$15.0K
= Free Cash Flow-$142.4M
Analysis
FY2025 free cash flow is -$142.4M. FCF conversion is 92.1% of net income. Operating cash flow was -$142.4M, with capex of -$15.0K. The largest bridge item is Stock-Based Comp at $19.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Oct 29, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 20, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 20, 2026 |
Does MLYS generate free cash flow?
Mineralys Therapeutics, Inc. (MLYS) generated -$142.43M of free cash flow in fiscal 2025.
How much operating cash flow does MLYS produce?
Operating cash flow was -$142.42M, before capital expenditures of $15,000.00.
Continue the stock analysis
Jump to another research area for this company.